key: cord-0998340-5yb98z81
authors: Poyatos, Paula; Luque, Neus; Eizaguirre, Saioa; Sabater, Gladis; Sebastián, Laura; Albesa, Íria Francisco; Peracaula, Míriam; Boixadé, Mireia; Orriols, Ramon; Tura-Ceide, Olga
title: Post-COVID-19 patients show an increased endothelial progenitor cell production.
date: 2022-01-24
journal: Transl Res
DOI: 10.1016/j.trsl.2022.01.004
sha: 98210165a4d7faed0877bce2ca2b1de1737f0674
doc_id: 998340
cord_uid: 5yb98z81

SARS-CoV-2, the cause of COVID-19, has generated a global emergency. The endothelium is a target of SARS-CoV-2, generating endothelial dysfunction, an essential step for the development of cardiovascular complications. The number of endothelial progenitor cells acts as an indicator of vascular damage. However, its role in SARS-CoV-2 is unknown. The aim of this study was to quantify the number of endothelial colony forming cells (ECFCs) and assess for the first time if there is a significant increase after SARS-CoV-2 infection. This study also evaluates whether the number of ECFC is related to the presence of pulmonary embolism (PE), and if this increase correlates with any of the clinical parameters studied. A total of 63 subjects were recruited including 32 subjects 3-months after overcoming COVID-19 and 31 healthy controls. The results confirm the presence of vascular sequelae in post-COVID-19 patients, with an abnormal increase in the number of ECFCs in blood circulation compared to controls (2,81±2,33 vs 1,23±1,86, p=0.001). There was no difference in ECFC production in COVID-19 who presented acute PE compared to those that did not (3,21±2,49 vs 2,50±2,23, p>0.05). The appearance of ECFC colonies in COVID-19 patients was significantly related to male gender (p=0.003), the presence of systemic hypertension (p=0.01) and elevated hemoglobin levels (p=0.02) at the time of ECFC isolation and lower PaO(2) levels (p=0.01) at admission. Whether these results indicate a prompt response of the patient to repair the damaged endothelium or reflect a post-infection injury that will persist in time is not known.

Recent studies showed that 30-70% of COVID-19 patients admitted to intensive care units (ICUs) developed blood clots in the deep veins of legs or lungs. Wichmann et al. 2 reported that out of the total 174 of autopsies from COVID-19 patients performed, 33% of the patients showed massive pulmonary embolism (PE) with or without underlying deep vein thrombosis, despite the absence of a history of venous thromboembolism, indicating the possibility of an in situ pulmonary thrombosis.

Endothelial progenitor cell (EPC) number and function are shown to be important biomarkers of vascular injury for a wide range of diseases 3 . Under pathological conditions, EPCs are thought to be mobilized from the bone marrow or from its niche in the vessel wall and recruited to sites of vascular injury with the aim to promote vascular regeneration 4,5. Kong et al. 5 demonstrated that EPC mobilization improved the repair of injured arteries by facilitating re-endothelialization. Similarly, Werner et al. 6 showed that vascular lesion and neointimal formation was moderated by bone marrow-derived progenitor cells. Recently, circulating bone marrow-derived CD34 + CD31 + CD146 -EPCs has been shown to be increased in COVID-19 patients 7 . However, the role of EPCs in SARS-CoV-2 is unknown.

EPCs considered to fulfil the criteria of a true EPC, have been named late outgrowth endothelial cells or endothelial colony forming cells (ECFCs) 8 . While the literature points out to the existence of more than one population of circulating EPCs, ECFC are the only ones with a robust clonogenic and proliferative potential, express endothelial markers, form tubule structures in vitro and support de novo angiogenesis when transplanted in vivo into immunodeficient mice 9 . Additionally, ECFCs can be expanded in vitro and operate as a disease in vitro model to understand the disease pathology and to develop potential novel treatments.

It is not fully understood which factors trigger the release of ECFCs into the blood´s circulation.

Previous reports have shown a significant increase of ECFCs 6-12h after coronary artery bypass surgery or burn injury, and 7 days after myocardial infarction 10, 11 . EPCs migrate in response to ischemia, to hypoxic sites following chemokine gradients, where they experience in situ differentiation and finally take part in the formation of new blood vessels 12 The present study aims to evaluate for the first time, whether an increase of ECFCs is present after SARS-CoV-2 infection and whether the number of ECFCs differs from COVID-19 patients who suffered an acute PE during admission than the patients that did not.

We recruited a total of n=32 3-months post-COVID-19 patients and n=31 healthy controls. The isolation of ECFC from all subjects and immunofluorescence analysis were performed as previously described 14, 15 (Figure 1A -B). Briefly, peripheral blood mononuclear cells (PBMC's) were isolated by buoyant density centrifugation over Ficoll-Paque Plus (GE Healthcare), resuspended in endothelial cell medium (ECM-2 medium, ScienceCell, Research Laboratories) supplemented with 20% fetal bovine serum (FBS hyclone, Cytiva) and 1% penicillin-streptomycin (P/S, Lonza); and plated onto type-1 rat-tail collagen-coated six-well tissue culture plates (BD Biosciences). Cells were incubated at 37°C, 5% CO 2 , and 95% relative humidity for 3-4 weeks 15 . The medium was changed every 2 days until the appearance of ECFC colonies. Cells were expanded in ECM-2 culture medium supplemented with 10% FBS and were cryopreserved in 90% FBS with 10% DMSO.

Colonies were counted after appearance, as an association of two or more individual cells together with the presence of a typical cobblestone endothelial morphology of ECFC. These colonies may appear on consecutive days and the number of colonies used in this study is the total number of colonies generated by a subject throughout their culture. The number of days it took for the first colony to appear were also quantified. All these parameters were evaluated between post-COVID-19 patients compared to healthy controls and between COVID-19 patients who suffered PE during admission than those that did not.

Statistical analyses were performed using GraphPad Prism 7 software, version 7.0e. Data are shown as mean±SD. Pairwise comparisons were performed using t-student test or Mann Whitney U test for non-normally distributed variables and Chi squared test in categorical variables. Pearson or Spearman rank correlation coefficient were used as a hypothesis test to study the dependence between two random variables. Statistical significance was assumed if p≤ 0.05.

Our results showed a significant increase in ECFC production in 3-months post-COVID-19 patients compared to healthy subjects. 27 COVID-19 patients out of the total of 32 had ECFC colonies at a particularly high level of 84,4% compared to 48,4% of ECFC isolation in healthy subjects ( Figure 2A ; Table 1 ). The average number of colonies in post-COVID-19 patients was also higher compared to healthy subjects ( Figure 2B ; Table 1 ) and the time needed for the colonies to appear also differed between patients and controls ( Figure 2C ; Table 1 ). Additionally, there was no difference regarding the presence and the number of ECFCs between COVID-19 patients who suffered PE during admission than those that did not (Table 1) .

In our series, the appearance of ECFC colonies in COVID-19 patients was significantly related to male gender (92,6%) and the presence of systemic hypertension (100%), both known risk factors for COVID-19 ( Figure 2D ). In addition, although troponin levels were significantly higher in 3 months post-COVID-19 patients compared to healthy controls ( Figure 2E and Table 1 ), no correlation was found between troponin levels and the number or appearance of ECFC colonies. Interestingly, patients who had higher numbers of ECFC colonies presented levels of hemoglobin (Hb) above the median value (≥14,5 g/dL) at the time of ECFC isolation and higher hypoxemia with PaO 2 levels below the median values (<80 mmHg) at admission (Figure 2 F-G). Bahlmann, et al. 16 showed that EPO was able to enhance progenitor cell mobilization in both patients and healthy subjects and increase at a dose-dependent manner EPC angiogenic potential in vitro. Our study is the first to show that 3 months post-COVID-19 patients with greater amounts of Hb levels and more severe hypoxic conditions, were able to generate higher numbers of ECFCs when compared to patients with higher PaO 2 levels. Whether these results indicate a counteractive or protective patient response to quickly restore the injured endothelium or it reflect greater vascular damage is not known and deserves further study.

Although there is literature about the importance of EPCs and their role in blood clot development and pulmonary embolism it remains largely understudied. Some observational studies hypothesize and support that EPCs would have a vascular protective role in venous thrombotic disease 17 . Others demonstrated that circulating EPCs can accelerate thrombus recanalization by restoring damaged endothelium and enhancing neovascularization 18, 19 . Certainty, the renewal of the endothelial layer is 6 crucial for the prevention of thrombus development or recurrency. In our series, there was no difference in the number of colonies generated between COVID-19 patients with or without PE and both sub-populations showed similar Hb levels. No significant differences were found between both populations in the clinical parameters analyzed (Table 1 and supplementary table 1 

SARS-CoV-2 identification in lungs, heart and kidney specimens by transmission and scanning electron microscopy

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Endothelial progenitor cells: Novel biomarker and promising cell therapy for cardiovascular disease

Endothelial Progenitor Cells Do Not Originate From the Bone Marrow

Cytokine-Induced Mobilization of Circulating Endothelial Progenitor Cells Enhances Repair of Injured Arteries

Bone Marrow-Derived Progenitor Cells Modulate Vascular Reendothelialization and Neointimal Formation

Circulating endothelial progenitors are increased in COVID-19 patients and correlate with SARS-CoV-2 RNA in severe cases

Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood

Systematic assessment in an animal model of the angiogenic potential of different human cell sources for therapeutic revascularization

Vascular Trauma Induces Rapid but Transient Mobilization of VEGFR2 + AC133 + Endothelial Precursor Cells

Mobilization of Endothelial Progenitor Cells in Patients With Acute Myocardial Infarction

Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1α

Mobilization of endothelial progenitor cells in sepsis

Generation of a Novel In Vitro Model to Study Endothelial Dysfunction from Atherothrombotic Specimens. Cardiovasc Drugs Ther 2021

Late outgrowth endothelial cells resemble mature endothelial cells and are not derived from bone marrow

Erythropoietin regulates endothelial progenitor cells

Patients with high levels of circulating endothelial progenitor cells (EPC) following at least three months of anticoagulation for unprovoked venous thromboembolism (VTE) are at low risk of recurrent VTE-Results from the ExACT randomised controlled trial

Endothelial progenitor cells accelerate the resolution of deep vein thrombosis

Endothelial progenitor cells are recruited into resolving venous thrombi